19:00Association of Phosphate-Containing versus Phosphate-Free Solutions on Ventilator Days in Patients Requiring Continuous Kidney Replacement Therapy -
Thompson Bastin, M. L., Stromberg, A. J., Nerusu, S. N., Liu, L. J., Mayer, K. P., Liu, K. D., Bagshaw, S. M., Wald, R., Morris, P. E., Neyra, J. A.
Clin J Am Soc Nephrol
Background and objectives Hypophosphatemia is commonly observed in patients receiving continuous KRT. Patients who develop hypophosphatemia may be at risk of respiratory and neuromuscular dysfunction and therefore subject to prolongation of ventilator support. We evaluated the association of (...)
19:00Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial -
Heerspink, H. J. L., Furtado, R. H. M., Berwanger, O., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Gasparyan, S. B., Tang, F., Windsor, S. L., de Souza-Dantas, V. C., del Sueldo, M., Frankel, R., Javaheri, A., Maldonado, R. A., Morse, C., Mota-Gomes, M., Shemin, D., Silva, O. L., Tognon, A. P., Twahirwa, M., Buenconsejo, J., Esterline, R., Oscarsson, J., Ambery, P., Langkilde, A. M., Kosiborod, M. N.
Clin J Am Soc Nephrol
Background and objectives Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients (...)
19:00Provider Perspectives and Clinical Outcomes with Inpatient Telenephrology -
Androga, L. A., Zoghby, Z., Ramar, P., Amundson, R. H., dUscio, M., Philpot, L. M., Thorsteinsdottir, B., Kattah, A. G., Albright, R. C.
Clin J Am Soc Nephrol
Background and objectives Despite the dramatic increase in the provision of virtual nephrology care, only anecdotal reports of outcomes without comparators to usual care exist in the literature. This study aimed to provide objective determination of clinical noninferiority of hybrid (...)
19:00SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function -
Suijk, D. L. S., van Baar, M. J. B., van Bommel, E. J. M., Iqbal, Z., Krebber, M. M., Vallon, V., Touw, D., Hoorn, E. J., Nieuwdorp, M., Kramer, M. M. H., Joles, J. A., Bjornstad, P., van Raalte, D. H.
Clin J Am Soc Nephrol
Background and objectives Sodium-glucose transporter 2 (SGLT2) inhibitor–induced uric acid lowering may contribute to kidney-protective effects of the drug class in people with type 2 diabetes. This study investigates mechanisms of plasma uric acid lowering by SGLT2 inhibitors in people with (...)
19:00GWAS of Hematuria -
Gagliano Taliun, S. A., Sulem, P., Sveinbjornsson, G., Gudbjartsson, D. F., Stefansson, K., Paterson, A. D., Barua, M.
Clin J Am Soc Nephrol
Background and objectives Glomerular hematuria has varied causes but can have a genetic basis, including Alport syndrome and IgA nephropathy. Design, setting, participants, & measurements We used summary statistics to identify genetic variants associated with hematuria in White British UK (...)
19:00APOL1 Kidney Risk Variants and Proteomics -
Chen, T. K., Surapaneni, A. L., Arking, D. E., Ballantyne, C. M., Boerwinkle, E., Chen, J., Coresh, J., Ko?ttgen, A., Susztak, K., Tin, A., Yu, B., Grams, M. E.
Clin J Am Soc Nephrol
Background and objectives The APOL1 risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How APOL1 risk variants relate to (...)
19:00Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients Receiving Long-Term Dialysis -
Wetmore, J. B., Herzog, C. A., Yan, H., Reyes, J. L., Weinhandl, E. D., Roetker, N. S.
Clin J Am Soc Nephrol
Background and objectives The association of apixaban compared with warfarin for the treatment of venous thromboembolism in patients receiving maintenance dialysis is not well studied. Design, setting, participants, & measurements We conducted a retrospective cohort study of Medicare (...)
19:00
One of the primary reasons for intensive care admission is shock. Identifying the underlying cause of shock (hypovolemic, distributive, cardiogenic, and obstructive) may lead to entirely different clinical pathways for management. Among patients with hypovolemic and distributive shock, fluid (...)
19:00
Since the description ischuria renalis by William Heberden (1), AKI has remained a prominent complication of critical illness. Beyond KRT, treatment has been limited by the capacity to phenotype this condition. Here, we chronicle the evolution of attempts to classify AKI, including the adoption (...)
19:00
An understanding of the processes underlying mass transfer is paramount for the attainment of adequate solute removal in the dialytic treatment of patients with kidney failure. In this review, engineering principles are applied to characterize the physical mechanisms behind the two major modes (...)
19:00
Fluid overload is a common complication in patients with CKD, particularly patients with kidney failure, a population with a very high risk for pulmonary edema. Lung ultrasound is now a well-validated technique that allows for reliable estimates of lung water in clinical practice. Several (...)